MedTrace Logo

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT05128825 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 310

Last updated 2026-05-01

No results posted yet for this study

Summary

This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive as determined by central review using the Sponsor's investigational clinical trial assay.

Conditions

  • High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Interventions

DRUG

azenosertib

Azenosertib (ZN-c3) will be administered orally.

Sponsors & Collaborators

  • K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-17
Primary Completion
2026-12-01
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • France
  • Italy
  • Poland
  • South Korea
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05128825 on ClinicalTrials.gov